Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:BLU TSE:CXR NASDAQ:ONC NASDAQ:TRIL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUBELLUS HealthC$0.00C$8.58▼C$19.90C$2.47B-0.2859,471 shs28,666 shsCXRConcordia InternationalC$0.00C$19.02▼C$417.00C$1.22BN/A4,054 shs73,541 shsONCBeOne Medicines$306.56+0.9%$290.24$253.95▼$385.22$33.35B0.49275,519 shs446,980 shsTRILDefiance Trillion Dollar Club Index ETF$19.86$18.12$5.80▼$20.96$2.09B2.081.87 million shsN/AThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUBELLUS Health0.00%0.00%0.00%0.00%0.00%CXRConcordia International0.00%0.00%0.00%0.00%0.00%ONCBeOne Medicines+0.86%-0.78%+15.91%-4.18%+21.58%TRILDefiance Trillion Dollar Club Index ETF0.00%0.00%0.00%0.00%+7.72%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUBELLUS HealthC$0.00C$8.58▼C$19.90C$2.47B-0.2859,471 shs28,666 shsCXRConcordia InternationalC$0.00C$19.02▼C$417.00C$1.22BN/A4,054 shs73,541 shsONCBeOne Medicines$306.56+0.9%$290.24$253.95▼$385.22$33.35B0.49275,519 shs446,980 shsTRILDefiance Trillion Dollar Club Index ETF$19.86$18.12$5.80▼$20.96$2.09B2.081.87 million shsN/AThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUBELLUS Health0.00%0.00%0.00%0.00%0.00%CXRConcordia International0.00%0.00%0.00%0.00%0.00%ONCBeOne Medicines+0.86%-0.78%+15.91%-4.18%+21.58%TRILDefiance Trillion Dollar Club Index ETF0.00%0.00%0.00%0.00%+7.72%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLUBELLUS Health 0.00N/AN/AN/ACXRConcordia International 0.00N/AN/AN/AONCBeOne Medicines 2.80Moderate Buy$390.9227.52% UpsideTRILDefiance Trillion Dollar Club Index ETF 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ONC, BLU, TRIL, and CXR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2026ONCBeOne Medicines BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$409.00 ➝ $403.007/7/2026ONCBeOne Medicines Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$436.00 ➝ $451.007/7/2026ONCBeOne Medicines Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$413.00 ➝ $416.007/3/2026ONCBeOne Medicines Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/1/2026ONCBeOne Medicines Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$396.006/4/2026ONCBeOne Medicines Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy6/2/2026ONCBeOne Medicines Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$425.00 ➝ $436.005/15/2026ONCBeOne Medicines Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$364.00 ➝ $367.005/7/2026ONCBeOne Medicines Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$395.005/7/2026ONCBeOne Medicines GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$410.00 ➝ $420.00(Data available from 7/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLUBELLUS HealthC$16K0.00N/A4.67C$2.91 per share0.00CXRConcordia InternationalC$569.62M0.00N/A5.85C$6.08 per share0.00ONCBeOne Medicines$5.34B6.30$3.94 per share77.77$39.77 per share7.71TRILDefiance Trillion Dollar Club Index ETF$150K13,903.44N/AN/A$2.56 per share7.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLUBELLUS Health-C$86.79M-C$0.96N/AN/AN/AN/A-26.76%-16.70%N/ACXRConcordia InternationalN/AC$351.680.07N/AN/AN/AN/AN/AN/AONCBeOne Medicines$286.93M$4.4768.5828.92N/A8.94%12.06%6.69%N/ATRILDefiance Trillion Dollar Club Index ETF-$59.35M$0.6232.04N/AN/AN/A-23.31%-18.66%N/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBLUBELLUS HealthN/AN/AN/AN/AN/ACXRConcordia InternationalN/AN/AN/AN/AN/AONCBeOne MedicinesN/AN/AN/AN/AN/ATRILDefiance Trillion Dollar Club Index ETFN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLUBELLUS Health0.3233.4216.40CXRConcordia International457.022.101.66ONCBeOne Medicines0.203.643.27TRILDefiance Trillion Dollar Club Index ETFN/A19.8219.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLUBELLUS Health90.41%CXRConcordia InternationalN/AONCBeOne Medicines48.55%TRILDefiance Trillion Dollar Club Index ETF87.15%Insider OwnershipCompanyInsider OwnershipBLUBELLUS Health10.26%CXRConcordia InternationalN/AONCBeOne Medicines6.19%TRILDefiance Trillion Dollar Club Index ETF9.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLUBELLUS Health74126.81 millionN/ANot OptionableCXRConcordia International22,50048.91 millionN/ANot OptionableONCBeOne Medicines12,000109.72 million102.93 millionN/ATRILDefiance Trillion Dollar Club Index ETF33105.00 million95.44 millionNo DataONC, BLU, TRIL, and CXR HeadlinesRecent News About These CompaniesThe Trillion-Dollar Club: Mega-Cap Stocks With Market Caps Over $1 TrillionJune 17, 2026 | money.usnews.comETF Prime: Murphy on the New Faces of the ETF BoomOctober 29, 2025 | etftrends.comEDefiance Trillion Dollar Club Index ETFOctober 21, 2025 | money.usnews.comTidal Trust II - Defiance Trillion Dollar Club Index ETFOctober 16, 2025 | money.usnews.comTrillion-Dollar Inflows: ETFs Become the Market’s New “Pulse”October 16, 2025 | nai500.comNThe Future Of Psychedelic-Inspired Therapeutics: No-Trip NeuroplastogensAugust 14, 2025 | lifescienceleader.comLPfizer Ends Mid-Stage Trial for CD47 Blood Cancer Drug, Citing Recruitment ProblemsJuly 1, 2025 | biospace.comBRatio Therapeutics and TerraPower Isotopes Sign Supply Agreement for Actinium-225 For Targeted RadiotherapeuticsJune 20, 2025 | finance.yahoo.comTrillium Therapeutics Stock Price HistoryMay 26, 2025 | investing.comTTI Consumer Power Tools, Inc. is Seeking an IP ParalegalSeptember 26, 2024 | ipwatchdog.comIAdvances in Drug Discovery & Development 2024September 8, 2024 | technologynetworks.comTWhen You Look Back in 5 Years, You'll Wish You'd Bought This $2 Trillion Artificial Intelligence (AI) StockJuly 30, 2024 | finance.yahoo.comGoogle Cloud unveils the Trillium TPU, its most powerful AI processor so farMay 14, 2024 | siliconangle.comSCachet Bicycle shakes off COVIDFebruary 25, 2024 | baytoday.caBRejuvenate your look with a trip to Fourth Avenue Medical AestheticsJanuary 30, 2024 | chch.comCTTI apprehends motorists for illegal removal of clamps, hunt for four others underwayJanuary 30, 2024 | bulawayo24.comBBridgeBio raises $1.25bn, and other biotech financingsJanuary 19, 2024 | pharmaphorum.comPRatio Therapeutics Raises $50M in Series B FinancingJanuary 17, 2024 | precisionmedicineonline.comPLeiomyosarcoma Drug Pipeline Report 2023 - ResearchAndMarkets.comNovember 10, 2023 | businesswire.comMirati Therapeutics Stock (NASDAQ:MRTX), Analyst Ratings, Price Targets, PredictionsNovember 8, 2023 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMDA Space Targets US Defense Market With $620M AcquisitionBy Jeffrey Neal Johnson | June 25, 2026AST SpaceMobile Announces Launch Date for Its Next 3 BlueBird SatellitesBy Jessica Mitacek | June 16, 2026AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion TargetBy Jeffrey Neal Johnson | July 10, 2026SpaceX Has Real Value—But These 3 Stocks Have Better Odds Right NowBy Bridget Bennett | June 28, 2026Is the Memory Rally Still Alive After the Semiconductor Sell-Off?By Jessica Mitacek | July 2, 2026ONC, BLU, TRIL, and CXR Company DescriptionsBELLUS Health TSE:BLUBluenergies Ltd. is engaged in the business of mineral exploration and the acquisition of mineral property assets in Canada. Its objective is to locate and develop economic precious and base metal properties of merit and to conduct its exploration program on the Lemon Lake Property.Concordia International TSE:CXRConcordia International Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies. This segment's products include Macrobid/Macrodantin to treat bladder infections, such as cystitis and urinary tract infections; Tetroxin drug for severe hypothyroid states; Eltroxin, levothyroxine sodium that treats patients with an underactive thyroid gland; and Fucithalmic, a topical gel treatment for patients suffering with a bacterial infection of the surface lining of the front of the eye. The Concordia North America segment provides Donnatalm, which is used as adjunctive therapy for irritable bowel syndrome; Zonegran, an anti-seizure drug indicated for adjunctive therapy in the treatment of partial seizures in adults with epilepsy; and Plaquenil and Plaquenil AG to treat rheumatoid arthritis and manage the complications of lupus, as well as suppress acute attacks from certain strains of malaria. This segment also offers photodynamic therapy with Photofrin for the treatment of certain forms of cancer that combines a photosensitizing agent with a specific type of laser that emits an exact wavelength of light and power to target cancer cells. The company sells its products through direct sales and local partnerships. The company was formerly known as Concordia Healthcare Corp. and changed its name to Concordia International Corp. in 2016. Concordia International Corp. is headquartered in Oakville, Canada.BeOne Medicines NASDAQ:ONC$306.56 +2.60 (+0.86%) Closing price 07/14/2026 04:00 PM EasternExtended Trading$315.15 +8.59 (+2.80%) As of 04:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.Defiance Trillion Dollar Club Index ETF NASDAQ:TRILTrillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet 3 Overlooked Energy ETFs Delivering Strong Returns and Income 3 Space Stocks That Could Outshine SpaceX After Its IPO 3 Energy Stocks Racing to Fix AI's Power Problem JPMorgan’s Q2 Strength Gives the Stock Rally New Support No Space For Panic: T-Mobile Shrugs Off The Starlink Threat Prepare for the Next Wave of Factory Automation With These 3 Standout Names Wedbush Pounds the Table—Buy Sandisk Before August 5 Earnings Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
